Professor of Medicine
Phone: 205-996-4744


Dr. Mannon received his B.A. and M.D. degrees from Boston University.  Between college and medical school, he spent a year at Trinity College, Dublin, Ireland, studying Latin and English in a Dual Mentorship program.  Following medical school, he completed his residency in internal medicine at Duke Universitiy, his clinical gastroenterology fellowship at Johns Hopkins University and his research gastroenterology fellowship back at Duke, where he joined the faculty as an Assistant Professor in 1991.  While on the Duke faculty, he became Chief of the Gastroenterology Section at the affiliated VA Medical Center and earned a Masters in Public Health from the University of North Carolina.  In 2000, he relocated to NIH to join the Mucosal Immunity Section, rising to Chief of the Inflammatory Diseases Research Unit in the Section.  While at NIH, he also became an Associate Professor of Medicine at the Uniformed Services University of the Health Sciences.  Dr. Mannon’s academic achievements include Alpha Omega Alpha, B.A. summa cum laude, M.D. cum laude, a Merck Award for Excellence, a VA Career Development Award, the European Crohn’s and Colitis Organization Prize for 2004 and an NIAID Merit Award for Outstanding Progress in Inflammatory Bowel Disease Research.

Dr. Mannon’s basic research interest focuses on the biology of the interaction between peptide YY and the neuropeptide YY 1 receptor in gut mucosal epithelium and in the brain.  His laboratory has documented the role of peptide YY as a growth factor for intestinal epithelium via epidermal growth factor.  Dr. Mannon’s clinical research interest is in the administration and evaluation of new biological agents for inflammatory bowel disease.  His group lead the clinical trial of anti-IL-12 p40 monoclonal antibody for the treatment of Crohn’s disease.

Selected Publications

  1. Mannon, P.J., Taylor, I.L., Kaiser, L.M. and Nguyen, T.D.  Cross-linking of neuropeptide Y to its receptor on rat brain membranes. Am. J. Physiol. 256:G637-G643, 1989.
  2. Mannon, P.J., Mervin, S.J. and Sheriff-Carter, K.D. Characterization of a Y1-preferring NPY/PYY receptor in HT-29 cells. Am. J. Physiol. 267:G901-G907, 1994.
  3. Mannon, P.J. and Raymond, J.R.  The neuropeptide Y/peptide YY Y1 receptor is coupled to MAP kinase via PKC and Ras in CHO cells. Biochem. Biophys. Res. Comm. 246:91-94,1998.
  4. Mannon, P.J. and Mele, J.M.  Peptide YY Y1 receptor activates mitogen-activated protein kinase and proliferation in gut epithelial cells via the epidermal growth factor receptor. Biochem. J. 350:655-661,2000.
  5. Mannon, P.J.  Peptide YY as a growth factor for intestinal epithelium. Peptides 23:383-388, 2002.
  6. Mannon, P.J., Fuss, I.J., Mayer, L., Elson, C.O., Sandborn, W.J., Dolin, B., Goodman, N., Groden, C., Hornung, R.L., Quezado, M., Neurath, M.F., Salfeld, J., Veldman, G.M., Schwertschlag, U. and Strober, W. Anti-IL-12 antibody for active Crohn’s disease. N. Engl. J. Med. 351:2069-2079, 2004.
  7. Fuss, I.J., Becker, C., Yang, Z., Groden, C., Hornung, R.L., Heller, F., Neurath, M.F., Strober, W. and Mannon, P.J.  Both IL 12p70 and IL-23 are synthesized during active Crohn’s disease are are down-regulated by treatment with anti-IL-12p40 monoclonal anitbody. Inflam. Bowel Dis. 12:9-15, 2006.
  8. Mannon, P.J., Fuss, I.J., Dill, S., Friend, J., Groden, C., Hornung, R., Yang, Z., Yi, C., Quezado, M., Brown, M. and Strober, W.  Excess IL-12 but not IL-23 accompanies the inflammatory bowel disease associated with common variable immunodeficiency. Gastroenterology 131:748-756, 2006.
  9. Strober, W., Fuss, I.J, and Mannon, P.J.  The fundamental basis of inflammatory bowel disease. J. Clin. Invest. 117:514-521, 2007.
  10. Mannon, P.J.  GAIN for Loss: Adalimumab for infliximab-refractory Crohn’s disease. Ann. Int. Med. 146:888-890, 2007.

Preventing, diagnosing, and caring for patients with digestive and liver-related conditions

The University of Alabama at Birmingham Division of Gastroenterology and Hepatology is spearheading the crusade to treat digestive and liver-related disease by promoting clinical education and research in all areas of the specialty. We enhance patient experiences by providing compassionate, competent, professional clinical care through expert physicians, well versed in treating severe and complex gastrointestinal and liver disorders.


Faculty, fellows and staff actively participate in developing new therapies associated with gastrointestinal disorders through comprehensive research facilities and programs within UAB.


The division’s fellowship programs deliver advanced training, superior knowledge and enhanced skills for gastroenterologists and hepatologists of the future.

Patient Care

GI & Hepatology sets the standard of patient care by developing compassionate, patient-centered, and clinically advanced physicians and staff.